Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Innovent and Anheart Report Novel TKI Effective in Phase II NSCLC Trial

publication date: Jun 7, 2022

Suzhou Innovent and Hangzhou AnHeart announced the Phase II trial of their partnered tyrosine kinase inhibitor was effective in TKI-naïve or Crizotinib-pretreated ROS1-positive NSCLC patients. The next-gen TKI targets ROS1 and NTRK. In 67 ROS1 TKI-naïve patients, the confirmed objective response rate was 92.5% and disease control rate 95.5%. In 38 crizotinib-pretreated patients, the cORR was 50% and DCR 78.9%. One year ago, Innovent acquired Greater China co-commercialization rights to the candidate from AnHeart in a deal that included an upfront payment, up to $189 million in milestones and royalties on sales. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital